Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD
SEQUEL was conducted at the Amsterdam UMC in the Netherlands with Everard (Jort) Vijverberg, M.D., Ph.D., acting as principal investigator.
- SEQUEL was conducted at the Amsterdam UMC in the Netherlands with Everard (Jort) Vijverberg, M.D., Ph.D., acting as principal investigator.
- The poster describing changes in brain wave patterns in adults with mild-to-moderate Alzheimer’s disease following 28-days of treatment with CT1812 or placebo will be on display through the conclusion of CTAD.
- In the SEQUEL study , CT1812-treated participants exhibited a statistically significant change in relative theta in the central region of the brain and consistent trends of improvement across all prespecified EEG parameters.
- “CT1812 treatment showed improvement of EEG parameters that are consistent in magnitude and effect size with previously reported trials,” explained Dr. de Haan.